New drug combo shows promise in small melanoma trial
NCT ID NCT03276832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether combining a topical cream (imiquimod) with an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced melanoma that has spread. Seven participants with stage IIIB to IV melanoma were enrolled. The goal was to see if the combination could shrink tumors and improve survival, while monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Could a common heart drug boost immunotherapy against melanoma?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers